Literature DB >> 2745267

Preliminary in-vitro studies of BMY-28232, the active metabolite of the BMY-28271 cephalosporin ester.

R M Jones1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2745267     DOI： 10.1093/jac/23.4.654

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  2 in total

1.  Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.

Authors:  R N Jones; M E Erwin
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

2.  Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.

Authors:  P R Murray; S D Allen; M E Erwin; E H Gerlach; R N Jones; F P Koontz; M A Pfaller; J A Washington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.